Abstract:Acute hepatitis C virus (HCV) infection is a global health concern with substantial geographical variation in the incidence rate. People who have received unsafe medical procedures, used injection drugs, and lived with human immunodeficiency virus are reported to be most susceptible to acute HCV infection. The diagnosis of acute HCV infection is particularly challenging in immunocompromised, reinfected, and superinfected patients due to difficulty in detecting anti-HCV antibody seroconversion and HCV ribonucleic acid from a previously negative antibody response. With an excellent treatment effect on chronic HCV infection, recently, clinical trials investigating the benefit of direct-acting antivirals (DAAs) treatment for acute HCV infection have been conducted. Based on the results of cost-effectiveness analysis, DAAs should be initiated early in acute HCV infection prior to spontaneous viral clearance. Compared to the standard 8-12 week-course of DAAs for chronic HCV infection, DAAs treatment duration may be shortened to 6-8 weeks in acute HCV infection without compromising the efficacy. Standard DAA regimens provide comparable efficacy in treating HCV-reinfected patients and DAA-naïve ones. For cases contracting acute HCV infection from HCV-viremic liver transplant, a 12-week course of pangenotypic DAAs is suggested. While for cases contracting acute HCV infection from HCV-viremic non-liver solid organ transplants, a short course of prophylactic or pre-emptive DAAs is suggested. Currently, prophylactic HCV vaccines are unavailable. In addition to treatment scale-up for acute HCV infection, practice of universal precaution, harm reduction, safe sex, and vigilant surveillance after viral clearance remain critical in reducing HCV transmission.

Updated treatment protocol for direct-acting antiviral agents for hepatitis C

Clinical efficacy and safety of ravidavir-based antiretroviral regimen in treatment of patients with chronic hepatitis C

Recent progress in direct-acting antiviral agents for chronic hepatitis C

Mechanism of resistance to direct-acting antivirals in hepatitis C treatment and management

[Highlights of the Guidelines of Prevention and Treatment for Hepatitis C (2019 Version)].

Clinical practice of direct-acting antiviral agents for chronic HCV infection

[Selection of Direct-Acting Antiviral Agents for Chronic Hepatitis C Infection].

Cutting-edge pharmacotherapy for hepatitis C virus infection: a comprehensive review

Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection

Recent Progress and Future Prospects of Direct-Acting Antiviral Agents for Chronic Hepatitis C

[Recent Advances in the Treatment of Hepatitis C in 2016].

Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2018 Clinical Practice Guideline

Recent Advance in Antiviral Drugs for Hepatitis C.

Long-term Outcomes in Patients with Chronic Hepatitis C in the Current Era of Direct-Acting Antiviral Agents

The Drug-Drug Interaction Potential of Antiviral Agents for the Treatment of Chronic Hepatitis C Infection

Key tasks in the era of direct-acting antiviral for hepatitis C in China

Brief introduction to the key points of the 2011 AASLD's practice guideline on treatment of genotype 1 chronic hepatitis C virus infection

Key points for the management of hepatitis C in the era of pan-genotypic direct-acting antiviral therapy

Acute hepatitis C virus infection: clinical update and remaining challenges

Efficacy and Safety of Combined Directly Acting Antivirals for Treatment of Chinese Chronic Hepatitis C Patients in a Real-World Setting

APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation